{"title":"关于 \"Atezolizumab 加贝伐单抗治疗无法切除的肝细胞癌患者因贝伐单抗特别关注的不良事件而放弃治疗的影响:IMbrave150Ⅲ期研究的探索性分析","authors":"Masatoshi Kudo, Kaoru Tsuchiya, Tatsuya Yamashita, Hironori Koga, Yuki Nakagawa, Masafumi Ikeda","doi":"10.1159/000539205","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":510489,"journal":{"name":"Liver Cancer","volume":"45 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’\",\"authors\":\"Masatoshi Kudo, Kaoru Tsuchiya, Tatsuya Yamashita, Hironori Koga, Yuki Nakagawa, Masafumi Ikeda\",\"doi\":\"10.1159/000539205\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":510489,\"journal\":{\"name\":\"Liver Cancer\",\"volume\":\"45 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000539205\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000539205","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’